Accession Number : ADA300057
Title : Novel Gene Therapy for Enhancing Anti-Tumor Immunity.
Descriptive Note : Annual rept. 1 Jul 94-30 Jun 95,,
Corporate Author : MARYLAND UNIV BALTIMORE COUNTY CATONSVILLE
Personal Author(s) : Baskar, Sivasubramanian
PDF Url : ADA300057
Report Date : 26 JUL 1995
Pagination or Media Count : 24
Abstract : This study aims to genetically modify the tumor cells and use them to induce efficient and vigorous anti-tumor immunity. Murine mammary carcinoma cell lines, 66.1 (metastatic and non-immunogenic) and 410.4 (non-metastatic and immunogenic) are used in the initial studies. To investigate whether or not costimulation of CD8+ T cells is sufficient to induce tumor rejection, the wild type 66.1 tumor cells (66.l/WT) were transfected with B7.I cDNA and stable lines and clones that constitutively express B7.I protein (66.1'B7.I+) were generated. Subcutaneous injection of live 66. 1'B7.I+ tumor cells into Balbic mice showed significant delay in the growth compared to 66.1/WT tumor cells. However, complete rejection was not seen, indicating that activation of CD8+ T cells alone is not sufficient to-induce tumor rejection. Further studies are under way wherein transfectants expressing both B7.I and class II MHC molecules will be used to induce tumor immunity in the syngenic host. These transfectants will help to understand the role of CD4+ T helper cells and CD8+ cytotoxic T cells in the induction of anti-tumor immunity.
Descriptors : *NEOPLASMS, *GENES, *IMMUNITY, *CANCER, INJECTION, MOLECULES, THERAPY, CLONES, MICE, CELLS(BIOLOGY), REJECTION, SUBCUTANEOUS TISSUE.
Subject Categories : Medicine and Medical Research
Genetic Engineering and Molecular Biology
Distribution Statement : APPROVED FOR PUBLIC RELEASE